176 related articles for article (PubMed ID: 24124338)
1. A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma.
He YF; Ji CS; Hu B; Fan PS; Hu CL; Jiang FS; Chen J; Zhu L; Yao YW; Wang W
World J Gastroenterol; 2013 Sep; 19(35):5910-6. PubMed ID: 24124338
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.
Cao W; Xu C; Lou G; Jiang J; Zhao S; Geng M; Xi W; Li H; Jin Y
Jpn J Clin Oncol; 2009 Sep; 39(9):582-7. PubMed ID: 19509000
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer.
Du J; Hu C; Zhang Y; Hu B; Wang F; Zhang Y
Anticancer Drugs; 2015 Jan; 26(1):101-5. PubMed ID: 25222530
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
[TBL] [Abstract][Full Text] [Related]
6. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
Gong Y; Ren L; Zhou L; Zhu J; Huang M; Zhou X; Wang J; Lu Y; Hou M; Wei Y
Cancer Chemother Pharmacol; 2009 Jul; 64(2):327-33. PubMed ID: 19048253
[TBL] [Abstract][Full Text] [Related]
8. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
10. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.
Lee MY; Jung KS; Kim HS; Lee JY; Lim SH; Kim M; Jung HA; Kim SM; Sun JM; Ahn MJ; Lee J; Park SH; Yi SY; Hwang IG; Lee SC; Ahn HK; Lim DH; Lee SI; Park KW
World J Gastroenterol; 2015 Apr; 21(14):4268-74. PubMed ID: 25892878
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J
Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Zhang F; Wang Y; Wang ZQ; Sun P; Wang DS; Jiang YX; Zhang DS; Wang FH; Xu RH; Li YH
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868295
[TBL] [Abstract][Full Text] [Related]
13. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
14. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
Akutsu Y; Shuto K; Kono T; Uesato M; Hoshino I; Shiratori T; Miyazawa Y; Isozaki Y; Akanuma N; Matsubara H
Hepatogastroenterology; 2012 Oct; 59(119):2095-8. PubMed ID: 22328303
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus.
Wang J; Chang J; Yu H; Wu X; Wang H; Li W; Ji D; Peng W
Cancer Chemother Pharmacol; 2013 Apr; 71(4):905-11. PubMed ID: 23370661
[TBL] [Abstract][Full Text] [Related]
16. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
Jin J; Xu X; Wang F; Yan G; Liu J; Lu W; Li X; Tucker SJ; Zhong B; Cao Z; Wang D
J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Guo JF; Zhang B; Wu F; Wang B; Xing H; Zhu GY; Nie XY; Peng J
Chin J Cancer; 2010 Mar; 29(3):321-4. PubMed ID: 20193118
[TBL] [Abstract][Full Text] [Related]
18. Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study.
Zhang MQ; Liu SP; Wang XE
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):821-7. PubMed ID: 20207507
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy.
Huang J; Zhou Y; Zhang H; Qu T; Mao Y; Zhu H; Quan L; Xing P; Wang J; He J; Xu N; Sun Y
Med Oncol; 2013 Mar; 30(1):343. PubMed ID: 23263828
[TBL] [Abstract][Full Text] [Related]
20. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.
Lu M; Wang X; Shen L; Jia J; Gong J; Li J; Li J; Li Y; Zhang X; Lu Z; Zhou J; Zhang X
Cancer Sci; 2016 Apr; 107(4):486-90. PubMed ID: 26797530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]